Substituted naphthyridine and quinoline compounds as MAO inhibitors
The invention provides a chemical entity of Formula (I) wherein R 1 , R 2 , R 3 , Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.
1. A compound selected from the groups consisting of:
pharmaceutically acceptable salts thereof.
2. The compound of compound of claim 1 selected from the groups consisting of:
pharmaceutically acceptable salts thereof.
3. The compound of compound of claim 1 selected from the groups consisting of:
pharmaceutically acceptable salts thereof.